ECO 2026: survodutide delivers renal and metabolic benefits in DKD model

The animal model used in the study signals proof-of-concept: the drug improved metabolic markers and kidney injury measures in a severe DKD model. The animal model used in the study signals proof-of-concept: the drug improved metabolic markers and kidney injury measures in a severe DKD model. Survodutide is a long-acting dual GCGR/GLP-1 aiming to mimic the metabolic actions of oxyntomodulin. Credit: PanuShot via Shutterstock.com. At this year’s European Congress on Obesity (ECO), during a poster session, researchers presented an analysis of the effects of survodutide in a state-of-the-art translational mouse model of advanced diabetic kidney disease (DKD). The findings raise…

Source: Clinical Trials Arena